Semax: ACTH-Derived Heptapeptide — BDNF Regulation & Neuroprotection Research

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, representing a stabilized analog of the ACTH(4-7) fragment extended with a C-terminal Pro-Gly-Pro tripeptide. The compound was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by V.N. Smirnov and colleagues as a metabolically stable derivative of the ACTH(4-10) fragment — a sequence known to influence memory and learning in rodent models. The Pro-Gly-Pro addition confers resistance to enzymatic degradation by prolyl endopeptidases and significantly extends the peptide's biological activity window in vivo compared to ACTH(4-7) alone.

Semax is classified as a nootropic in Russia, where it has regulatory approval as a nasal drop formulation. From a research perspective, the peptide has attracted significant interest due to documented effects on brain-derived neurotrophic factor (BDNF) gene expression in brain tissue preparations, interactions with melanocortin receptor subtypes (particularly MC4R), and modulation of neuroinflammatory gene programs in preclinical ischemia models. These properties make Semax a mechanistically diverse tool for studying how ACTH-derived peptides interface with neurotrophin signaling pathways.

Biochemical Identity & Structural Properties

Proposed Mechanisms of Action

BDNF and Neurotrophin Gene Regulation

The most extensively documented molecular effect of Semax in preclinical research is its upregulation of BDNF (brain-derived neurotrophic factor) mRNA and protein expression in brain tissue preparations. Dolotov et al. (2006) published data demonstrating that Semax administration in rats produced dose-dependent increases in BDNF mRNA levels in the frontal cortex and hippocampus, with concurrent increases in NGF (nerve growth factor) mRNA in select brain regions. The temporal profile of BDNF upregulation — peaking at 1–3 hours post-administration in rodent brain preparations — has been used to characterize the signaling intermediaries involved, with research examining roles for cAMP-response element binding protein (CREB) and MAPK/ERK pathway activation upstream of BDNF transcription.

Melanocortin Receptor Interactions

As a derivative of the ACTH(4-7) core, Semax retains the His-Phe-Arg-Trp pharmacophore present in melanocortin ligands, suggesting potential interactions with melanocortin receptors (MC1R–MC5R). Research has examined Semax's binding profile and functional effects at MC4R, which is expressed in the central nervous system and has established roles in energy homeostasis and cognitive function research. MC4R activation by melanocortin peptides has been linked to cAMP elevation and downstream effects on synaptic plasticity markers in hippocampal cell preparations, positioning Semax as a potential tool for studying MC4R biology in neural contexts.

Neuroinflammatory Gene Program Modulation

Studies in rodent focal ischemia models have examined changes in gene expression profiles in ischemic brain tissue following Semax administration, using microarray and quantitative RT-PCR approaches to characterize transcriptional responses. Published data from Levitskaya et al. and related groups documented modulation of genes involved in neuroinflammation, oxidative stress response (HO-1, SOD2), and vascular biology (VEGF) in ischemia-challenged brain tissue, providing a gene expression framework for understanding how the peptide interfaces with the transcriptional response to neural injury in animal models.

Summary of Published Research Findings

• BDNF mRNA upregulation: Quantitative RT-PCR studies in rodent brain tissue documented statistically significant increases in BDNF mRNA in the frontal cortex and hippocampus following Semax administration, with the effect strongest in animals under conditions of baseline neurotrophin reduction (aged animals, stress models).
• Cognitive task performance in animal models: Rodent behavioral research (Morris water maze, passive avoidance paradigms) has examined Semax's effects on spatial memory acquisition and retention, generating data on the behavioral correlates of BDNF upregulation in hippocampal-dependent tasks.
• VEGF expression in ischemia models: Studies examining focal cerebral ischemia in rodents documented upregulation of VEGF (vascular endothelial growth factor) mRNA in ischemic penumbra tissue following Semax, providing data on angiogenic gene program modulation in neural injury research contexts.
• Metabolic stability characterization: In vitro enzymatic degradation studies compared Semax's resistance to prolyl endopeptidase and leucine aminopeptidase relative to ACTH(4-7), establishing the structural basis for its extended biological activity compared to the parent fragment.

Key Published References

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analog of ACTH(4-7) with nootropic properties, activates dopaminergic and serotonergic brain systems in rodents. Neurochemical Research, 31(12), 1493–1499. PMID: 17115262

Dolotov OV, Karpenko EA, Seredenin SB, Grivennikov IA. (2006). Semax and its C-terminal tripeptide PGP activate BDNF synthesis in the hippocampus of rat brain. Doklady Biological Sciences, 411, 493–495. PMID: 17193717

Mironova VI, Evdokimova NR, Tret'yakova LV, Dolotov OV, Grivennikov IA. (2007). [Effects of Semax on the content of neurotrophins and their receptor TrkB in the rat hippocampus and frontal cortex]. Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova, 93(7), 731–737. PMID: 17847668

Storage & Laboratory Handling

• Lyophilized powder: −20°C in desiccated, light-protected conditions. Stable for 24+ months.
• Reconstitution: Dissolve in sterile saline or PBS. Water-soluble; no organic solvents required. Methionine (Met1) is susceptible to oxidation — minimize prolonged air exposure in solution.
• Working solutions: Prepare fresh aliquots; store at 4°C for up to 7 days. Freeze-thaw cycles degrade the peptide — aliquot before freezing.